Prothrombinase complex assembly, in real time, on platelets adherent to immobilized von Willebrand Factor (vWf) was examined by total internal reflection fluorescence spectroscopy (TIRFS). Electron microscopy showed that the platelets adhered to vWf in a largely unactivated state and could be activated by thrombin. Antibody binding to glycoprotein (GP) Ib and functional GPIIb-IIIa receptor molecules on adherent platelet membranes monitored by TIRFS also indicated that platelets adhered in a largely unactivated state. Maximal expression of the receptor form of GPIIb-IIIa detected by antibody binding was seen only after thrombin stimulation of the adherent platelets. Antibody binding to GPIb was detected on adherent platelets. A reduction in antibody binding was observed after thrombin stimulation of the platelets, indicating a change in GPIb as a consequence of thrombin stimulation of the platelets. The binding of the protein components of the prothrombinase complex to adherent and thrombin-stimulated adherent platelets was then studied individually. Factor Va bound to adherent and thrombin-stimulated adherent platelets with an estimated K a of 58 nmoI/L. Minimal factor Xa binding was observed on adherent platelets before thrombin stimulation. Factor Xa binding was, however, readily observed on thrombin-stimulated adherent platelets. This factor Xa binding was not saturable, and no K d value could be estimated. Direct measurement of prothrombinase complex assembly was demonstrated by using an energy transfer phenomenon between fluorescein-labeled factor Va and rhodamine-labeled factor Xa. Prothrombinase complex assembly was observed on both adherent and thrombin-stimulated adherent platelets. The estimated K A for the factor Va/factor Xa interaction was 4 nmol/L. TIRFS demonstrated that adherent platelets have the ability to support prothrombinase complex assembly, as shown by a direct energy transfer reaction between fluorescently labeled factors Va and Xa. (Arterioscler Thromb.
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Prothrombinase complex assembly, in real time, on platelets adherent to immobilized von Willebrand Factor (vWf) was examined by total internal reflection fluorescence spectroscopy (TIRFS). Electron microscopy showed that the platelets adhered to vWf in a largely unactivated state and could be activated by thrombin. Antibody binding to glycoprotein (GP) Ib and functional GPIIb-IIIa receptor molecules on adherent platelet membranes monitored by TIRFS also indicated that platelets adhered in a largely unactivated state. Maximal expression of the receptor form of GPIIb-IIIa detected by antibody binding was seen only after thrombin stimulation of the adherent platelets. Antibody binding to GPIb was detected on adherent platelets. A reduction in antibody binding was observed after thrombin stimulation of the platelets, indicating a change in GPIb as a consequence of thrombin stimulation of the platelets. The binding of the protein components of the prothrombinase complex to adherent and thrombin-stimulated adherent platelets was then studied individually. Factor Va bound to adherent and thrombin-stimulated adherent platelets with an estimated K a of 58 nmoI/L. Minimal factor Xa binding was observed on adherent platelets before thrombin stimulation. Factor Xa binding was, however, readily observed on thrombin-stimulated adherent platelets. This factor Xa binding was not saturable, and no K d value could be estimated. Direct measurement of prothrombinase complex assembly was demonstrated by using an energy transfer phenomenon between fluorescein-labeled factor Va and rhodamine-labeled factor Xa. Prothrombinase complex assembly was observed on both adherent and thrombin-stimulated adherent platelets In vivo, one of the initial responses to vascular injury is presumably the adherence of platelets to elements of the exposed subendothelium of the damaged vessel wall. Platelet attachment to the subendothelial matrix is mediated in part by the binding of platelet membrane glycoprotein (GP) Ib to matrixincorporated von Willebrand factor (vWf).
14 This mechanism is particularly important under conditions of high shear rate, such as that observed in the microvasculature. 5 - 6 Because GPIb is constitutively expressed as an active receptor on the unactivated platelet membrane, binding of GPIb to vWf does not require platelet stimulation. 7 However, subsequent to platelet stimulation with thrombin, the number of GPIb receptor molecules is reduced. 813 Stimulation of platelets by agonists such as thrombin also induces granule release, platelet spreading on the vessel surface, and aggregation. 1415 The processes of spreading and aggregation are dependent on the receptor form of the GPIIb-IIIa complex, which is only expressed on the membranes of activated platelets. 16 23 The GPIIb-IIIa receptor corn-binding of an antibody to a surface antigen on SAOS-2 cells 33 and the binding of tissue plasminogen activator to human umbilical vein endothelial cells. 34 The technique has also been used by other laboratories to study the binding of prothrombin to planar phospholipid membranes 35 and the binding of immunoglobulin (Ig) G to a mouse IgG receptor reconstituted in substrate-supported planar membranes. 36 ' 37 Other roles for TIRFS technology include the examination of protein adsorption at solid-liquid interfaces 38 and the adsorption of proteins on polymer films. 39 Under the experimental conditions chosen, there is selective excitation of bound fluorescent probes at the interface without significant excitation of fluorescent molecules in the bulk solution. 33 The binding measurements can also be carried out in a continuous manner, in real time, under equilibrium conditions.
A static, adherent platelet model was developed to approximate the initial conditions that occur during vessel injury in vivo. The initial stage of platelet adherence to the subendothelium, the deposition phase, is described by Baumgartner et al. 40 - 41 Human platelets were allowed to adhere to a quartz surface coated with vWf. Because these experiments were not performed under flow conditions, only the initial deposition phase of platelet adherence to the surface was addressed in this model, not the subsequent phases of platelet spreading and granule release, 40 -41 although these phases could be approximated after thrombin stimulation of the adherent platelets. Adherent and thrombinstimulated adherent platelets were examined by using conventional and TIRFS techniques. TIRFS binding studies of antibodies to platelet surface GPIb and the GPIIb-IIIa complex were used to determine the activation states of the surface-adhered platelets before and after thrombin stimulation. Factor Va and factor Xa binding were observed with TIRFS under a variety of conditions, including conditions in which an energy transfer phenomenon between fluorophores on the two proteins would definitively show complex assembly.
Methods

Protein Purification
Factor Va and factor X were isolated from bovine plasma. 4243 Factor Xa was prepared from factor X by using purified factor X activator from Russell's viper venom 44 followed by affinity chromatography. 45 Prothrombin was purified from fresh frozen human plasma 43 and was subsequently activated to generate thrombin. 46 The anti-GPIb antibody AP-1 was purified from ascites by fast protein liquid chromatography using Mono Q ion-exchange chromatography. 47 Factor Va, factor Xa, thrombin, and antibody concentrations were determined by using the appropriate extinction coefficients: E' % , cra , ^ nm =17. 51 and was further purified by chromatography on a Sepharose CL-4B (Pharmacia) column. The vWf-containing fractions were pooled and run on a 2% agarose gel to verify the presence of high-molecular-weight multimers. 52 The protein concentration of the vWf pool was determined by protein assay. 53 
Antibodies
PAC-1, an anti-GPIIb-IIIa murine monoclonal IgM antibody that recognizes only the receptor form of the complex, 54 was the generous gift of Sanford J. Shattil, School of Medicine, University of Pennsylvania, Philadelphia. Lyophilized ascites containing AP-1, a murine monoclonal IgG anti-GPIb antibody, 22 was kindly provided by Thomas J. Kunicki, The Blood Center of Southeastern Wisconsin, Milwaukee. Purified murine monoclonal IgG antibody aBFV-4 was provided by William R. Church, Department of Biochemistry, University of Vermont, Burlington. aBFV-4 is an antibovine factor Va antibody that inhibits the binding of factor Xa to factor Va in the bovine system. 
Fluorescence Labeling
Both PAC-1 and AP-1 were labeled with fluorescein-5-isothiocyanate (FITC) 10% adsorbed on Celite (Molecular Probes). 57 Factor Xa was active-site labeled with fluorescein glutamylglycinylarginyl chloromethyl ketone (fluorescein EGRck Xa) or tetramethylrhodamine glutamylglycinylarginyl chloromethyl ketone (rhodamine ERGck Xa). 58 Fluorescein EGRck was prepared from 5-(and 6-)carboxyfluorescein succinimidyl ester (Molecular Probes), and rhodamine EGRck was prepared by using 5-(and 6-) carboxytetramethylrhodamine succinimidyl ester (Molecular Probes). 58 EGRck was supplied by Haematologic Technologies Inc. Factor Va was labeled on cysteine with fluorescein; 5-maleimide (Molecular Probes). 59 
Platelet Isolation
Venous blood was drawn from consenting individuals who had not taken aspirin in the previous 10 days. Blood was anticoagulated with acid-citrate-dextrose (ACD), 6 mL ACD/30 mL blood. Heparin (50 U/mL) was added to the ACD before blood collection. Platelets were isolated from 60 mL blood/ACD by using a modification of the technique of Mustard et al. 60 The blood was centrifuged at 120g for 15 minutes at 26°C to obtain platelet-rich plasma. Platelets were isolated from platelet-rich plasma by centrifugation at 240g for 15 minutes at 26°C. The platelets were washed one time in 10 mL buffer containing 13 mmol/L NaCl, 2 mmol/L KC1, 12 mmol/L NaHCO 3 , 0.3 mmol/L NaH 2 PO 4 , 2 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , 5.5 mmol/L dextrose, and 0.35% bovine serum albumin, pH 7.35 (Tyrode's buffer). Platelets were sedimented from the wash buffer at 240g for 5 minutes at 26°C and were resuspended in 2 mL of the above buffer containing 5 mmol/L 7V-2-hydroxyethylpiperazine-A''-2-ethanesulfonic acid (HEPES-Tyrode's buffer). The platelets were incubated at 37°C until use, typically 15 minutes. Three platelet washes, according to the procedure of Mustard et al, 60 were also performed. No difference in platelet binding to vWf or in thrombin activation of the platelets was detected between platelets washed one time or three times, so the faster procedure was used.
TIRFS Instrumentation
An argon ion laser (Spectra Physics 2025-05) provided the excitation light source for TIRFS. The light power was modulated with an acoustic-optic modulator (Newport EOS) and a mechanical chopper (Stanford Research Corp) so that the beam power at the sample was 20 fiW. The beam was focused through the 73°a ngle in the TIR element (Optical Spectrum Technologies) and into a fused-silica lens (F=20 mm) generating an elliptical reflection spot (R=2 mm, r = l mm) centered over the light collection optics. An electronic shutter with a beam trap (Vincent Associates) blocked the incident beam between data readings, preventing sample heating and photobleaching of the fluorophore. The TIR element was mounted on a Zeiss inverted microscope equipped with a photomultiplier tube (Hammamatsu) at the top of the optical column. The configuration of the design allowed for excitation of fluorescence and signal collection through the cell layer. Fluorescence was detected only from cell-bound fluorescent proteins. The contribution from fluorescent molecules in solution was minimal. 33 
TIRFS Sample Preparation
Sections of glass tubing with a 1-cm interior diameter were attached with optical cement to lxl-inxl-mm spectroscopic-grade UV quartz slides (Harrick Scientific Inc) to form sample wells capable of holding a 400-jtiL volume. Each slide was cleaned extensively and was dried at 60°C before plasma cleaning in an air plasma cleaner. The individual wells were coated with 10 fig/mL vWf in 50 mmol/L carbonate coating buffer, pH 9.0, for 15 hours at 4°C, incubated with 10% ovalbumin for 2 hours at 26°C, and washed three times with HEPES-Tyrode's buffer before the addition of platelets. Approximately lxlO 8 platelets in 300 yiL HEPES-Tyrode's buffer were added to each sample well and were allowed to adhere for 15 minutes at 26°C before washing three times with HEPES-Tyrode's buffer. The washes containing the nonadherent platelets were collected, and the platelets were counted. The number of adherent platelets was determined based on the initial platelet count and the number of nonadherent platelets. An average of 1.8xl0 7 ±0.6xl0 7 platelets adhered per well. The samples were kept at 37°C, and binding studies were performed within 6 hours of platelet isolation.
TIRFS Binding Studies
TIRFS 33 was used to examine binding of fluorescently labeled proteins to adherent platelets. An excitation wavelength of 488 nm to excite fluorescein emission was used for all experiments. A 520-nm cutoff filter was used to select for fluorescein emission.
All binding studies were performed at 37°C under stirred conditions. The well position and beam alignment were adjusted before the study to minimize the background signal due to light scatter. vWf-coated wells with no adherent platelets served as controls. The signals from the control experiments with vWf alone were subtracted from the sample signals to eliminate the nonspecific background contribution to the binding signal. Aliquots of the protein being studied were added to the sample well or the control well, and the bound fluorescent signal was collected over time, typically 30 minutes. The signals from 10-second excitation pulses were collected at increasing intervals, with a final interval of 3 minutes. At least three binding measurements were performed for each set of experiments.
TIRFS binding studies with FITC PAC-1 and FITC AP-1 were performed as continuous measurements. The antibody being examined was added to the bulk solution above a layer of adherent platelets. When a binding equilibrium was reached, 1 U/mL thrombin was added to stimulate the platelets. The signal collection was continued until the signal reached a new binding equilibrium value.
Factor Va binding studies were performed separately on adherent and thrombin-stimulated adherent platelets. Aliquots of factor Va were added to the well as a continuous titration. The fluorescent signal was allowed to reach a plateau before the addition of each aliquot. The total added volume did not significantly change the initial volume. For studies of binding to thrombinstimulated adherent platelets, 1 U/mL thrombin was added to the well 5 minutes before the initiation of the binding titration. Factor Xa binding studies were performed in the same manner.
The energy transfer measurements to detect prothrombinase complex assembly were performed on adherent and thrombin-stimulated adherent platelets. The platelets were preincubated for 20 minutes with 100 nmol/L fluorescein-labeled factor Va (saturating conditions). Rhodamine EGRck Xa was titrated into the solution above the adherent platelets. The incidentbeam wavelength was set at 488 nm to excite fluorescein emission from the probe on factor Va. A 560-nm cutoff filter was used to select for the energy transfer signal generated by rhodamine emission from the rhodamine probe on factor Xa. In a control experiment, rhodamine EGRck Xa was titrated into the solution above a layer of adherent platelets preincubated with 100 nmol/L unlabeled factor Va. aBFV-4 was used to determine the specificity of the interaction between fluorescein-labeled factor Va and rhodamine-labeled factor Xa. After titration of rhodamine EGRck Xa onto the fluoresceinlabeled factor Va bound to the adherent platelets, 4 /imol/L aBFV-4 was added to the solution phase to determine if the energy transfer signal was due to complex assembly.
The TIRFS binding data were fit to a nonlinear equation defined by Pearce et al, 61 Fob
where F obs is the measured fluorescence (sample fluorescence with background fluorescence subtracted), F max is the maximum possible fluorescence if all binding sites are occupied, K A is the apparent dissociation constant, and [P] is the total concentration of added protein. The data were fit with K d and F max as free parameters. Values for these parameters were determined from a plot of (Fobs)" 1 versus ([P])" 1 . The plotted TIRFS data represent the average data for a number (n>3) of repeated measurements with different donors. The error limit is representative of variability in the individual data sets.
SEM and TEM Sample Preparation
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) samples were prepared simultaneously with TIRFS samples. Glass coverslips were sectioned, and 0.5-cm-square pieces were placed in 24-well cell-culture plates. The slips were coated with 10 /xg/mL vWf in 50 mmol/L carbonate coating buffer, pH 9.0, for 15 hours at 4°C and were incubated with 10% ovalbumin for 2 hours at 26°C before washing extensively with HEPES-Tyrode's buffer. Approximately 2xlO 8 platelets were added per well and were allowed to adhere for 15 minutes at 26°C. The unadhered platelets were removed by washing the wells with HEPES-Tyrode's buffer. Fresh buffer was added, and half of the platelet samples were activated by the addition of 1 U/mL thrombin to the well. The samples were fixed for SEM or TEM within 1 hour of preparation. Incubations of 2 to 3 hours before fixation were also performed to ensure that activation of the platelets was thrombin dependent and did not occur spontaneously over time. One milliliter of 2.5% glutaraldehyde in Millonig's buffer (41.5 mL of 2.26% NaH 2 PO 4 and 8.5 mL of 2.52% NaOH, pH 7.4) was added to the adherent and thrombin-stimulated adherent platelets and incubated at 4°C for 1 to 2 hours. The platelets were washed four times with Millonig's buffer, and 1 mL of 1% osmium was applied for 30 minutes. Dehydration of the platelets was accomplished with a graded series of ethanol solutions (10% to 100%). The samples for SEM were then critical-point dried in a CO 2 system, mounted on specimen stubs, and gold-coated in a sputtering device. The samples for TEM were stained with ethanolic uranyl acetate (2% uranyl acetate in 100% ethanol) for 20 minutes after the dehydration step and were rinsed four times with 100% ethanol. The tissue was infiltrated with 50% propylene oxide/50% ethanol for 15 minutes followed by two incubations with 100% propylene oxide for 15 minutes each. The TEM samples were incubated with 50% propylene oxide/50% Epon-Araldite resin overnight. Epon-Araldite resin (100%) was added for 3 to 4 hours before polymerization at 60°C overnight. Sections (0.08 to 0.10 ju.m) were cut on a diamond knife and were stained for 4 minutes with filtered, kalcinated lead citrate. The SEM samples were viewed with a Joel 100CX electron microscope, and the TEM samples were viewed with a Phillips EM300 electron microscope.
Results
Washed platelets adherent to immobilized vWf were used as a model system to study the role of adherent platelets in the initial deposition phase on the subendothelial surface. Approximately 1.8±O.6xlO 7 platelets adhered per TIRFS sample well (cross-sectional average of 5.7xlO 6 platelets/cm 2 ). The number of adherent platelets appeared to be dependent on the surface area coated with vWf, as it did not vary significantly with either different donors, different platelet concentrations initially added to the wells, or different incubation times (5 to 20 minutes) before removing the nonadherent platelets.
SEM was used to examine the surface appearance and activation states of the adherent platelets before and subsequent to thrombin stimulation. Unactivated platelets in suspension are largely discoid in shape with no protrusions, whereas activated platelets are flattened with multiple extensions.
15 ' 62 Adherent platelets ( Fig  1A) showed clear evidence of pseudopod extension and some spreading. However, the platelets were still round and individually well defined and did not appear to be fully activated. The vWf-adherent platelets resembled the "dendritic" platelets seen when bovine platelets are first exposed to a coated surface, 63 or the "contact" phase platelets described by Baumgartner et al 40 - 41 in the deposition phase of platelet interaction with a subendothelial surface. After thrombin activation, the appearance of the adherent platelets changed dramatically. The advanced degree of platelet spreading resulted in complete loss of individual platelet definition (Fig IB) . These platelets clearly show the fully spread "fried egg" form of platelets activated on a glass surface. 64 These platelets resemble the platelets seen in the later stages of platelet deposition on the subendothelium under flow conditions, when platelets have spread on the surface and released granule contents. 40 - 41 The differences in platelet morphology between adherent and thrombin-stimulated adherent platelets suggested that platelets adhered to vWf in a mostly unactivated state. The adherent platelets could then be fully activated by the addition of 1 U/mL thrombin. This is in contrast to platelet adherence to vWf under flow conditions, in which adherence leads to platelet activation even in the absence of added agonists.
-
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TEM was used to further examine the activation states of the adherent platelets. With TEM, the intercellular platelet granules can be visualized. The granules remain intact in unactivated platelets, whereas platelet activation induces granule release. 67 TEM clearly showed that platelet granules were still intact in the vWf-adherent platelets (Fig 1C) . Thrombin treatment of the adherent platelets resulted in complete degranulation (Fig ID) . The TEM results were consistent with the SEM findings that platelets adhere to vWf in an unactivated state. The TEM sample of adherent platelets was cut horizontally through the platelets to look at the field as it was viewed for SEM. The spacing between the platelets indicated that platelet adherence to vWf did not result in platelet aggregation. The TEM sample of thrombin-stimulated adherent platelets was cut vertically through the platelets, vWf coating, and glass coverslip to visualize the platelets adhering to vWf. Platelet aggregation was evident in the thrombin-stimulated sample. Thus, in our model system, platelet activation and aggregation were dependent on thrombin stimulation and not on the initial vWf adherence event. This is a potential advantage of this model relative to flow systems in which platelet adherence under flow conditions results in platelet activation.
-
66
TIRFS antibody binding studies were performed in conjunction with the electron microscopy work to follow the expression of GPIb and the GPIIb-IIIa receptor complex on the platelet membranes. GPIb mediates adhesion of unactivated platelets to vWf; however, after thrombin activation, the receptor form of GPIb is significantly reduced. 813 In contrast to GPIb, the GPIIb-IIIa complex is present as a functional receptor only on the membranes of activated platelets. 16 " 23 The GPIIb-IIIa receptor complex recognizes vWf and fibrinogen as well as several other adhesive proteins. GPIIb-IIIa receptor complex, is also influenced by the activation state of the platelet. AP-1, an antibody to GPIb, 22 -68 was used to monitor the expression of GPIb on the surface of adherent platelets. TIRFS binding studies with FITC AP-1 showed significant binding of the antibody to the vWf-adherent platelets (Fig 3) . Thrombin stimulation of the adherent platelets induced a dramatic decrease in the fluorescent signal from bound AP-1 (Fig 3) . The threefold decrease in the fluorescent signal indicated that GPIb was no longer accessible to the antibody on thrombin-stimulated adherent platelets. Whereas adherent platelets show morphological differences from unactivated platelets in suspension, they show similar expression of the GPIIbIIIa receptor complex and identical expression of GPIb.
7~23 Thrombin-induced changes in receptor expression on adherent platelets show strong similarity to the changes induced in thrombin-treated platelets in suspension.
The assembly of the prothrombinase complex on the membranes of adherent and thrombin-stimulated adto the unactivated GPIIb-IIIa complex. The latter explanation is unlikely since minimal binding of PAC-1 is seen with platelets in suspension. 54 Platelet adhesion to vWf and subsequent pseudopod formation may be sufficient to induce expression of some of the GPIIb-IIIa receptor complexes, allowing binding of PAC-1.
Thrombin stimulation of the adherent platelets greatly increased the binding of FITC PAC-1. The signal was 330% greater than that measured on adherent platelets before thrombin stimulation (Fig 2) . The large increase in the fluorescent signal indicated a significant increase in the number of GPIIb-IIIa receptor complexes recognized by the PAC-1 antibody. Although adherent platelets snowed evidence of pseudopod extension, adherence alone was not capable of stimulating full expression of the GPIIb-IIIa receptor complexes. As anticipated, thrombin stimulation was required for complete receptor expression, again indicating that platelets adhered to vWf in an unactivated state.
Expression of GPIb, although not an activation-specific marker such as the expression of a functional herent platelets was then examined. The binding of the protein components of the complex, the serine protease factor Xa and its cofactor, factor Va, were initially studied individually. The binding of fluorescein-labeled factor Va to adherent platelets reached saturation at a concentration of 80 nmol/L, approximately fourfold higher than the plasma concentration of factor V (Fig  4) . The fluorescent signal showed no increase in inten- sity at higher concentrations (up to 100 nmol/L). Thrombin stimulation of the adherent platelets did not change the binding properties of factor Va (Fig 4) . The estimated K t for the binding of factor Va to adherent and thrombin-stimulated adherent platelets was 58 nmol/L±2 nmol/L.
Very little binding of fluorescein EGRck factor Xa was detected on vWf-adherent platelets (Fig 5) . Substantial binding of factor Xa (in the absence of added factor Va) was observed on thrombin-stimulated adherent platelets (Fig 5) . Because factor Va is released from the platelets on activation, 69 -70 the factor Xa binding results suggested that the binding of factor Xa to thrombin-stimulated adherent platelets was at least partially dependent on plateletreleased factor Va. However, the binding of factor Xa did not saturate on thrombin-stimulated adherent platelets even at a solution concentration of 400 nmol/L, which is approximately fourfold greater than the normal plasma concentration of factor X. The addition of 2 to 10 yumol/L dansylarginine ^-(S-ethyl-l.S-pentanediy^amide, an active-site-directed thrombin inhibitor, 72 did not change the factor Xa binding profile.
To examine only specific factor Va/factor Xa complex formation, factor Va and factor Xa were labeled with fluorescein and rhodamine, respectively. The emission of fluorescein at 520 nm overlaps the excitation profile of rhodamine sufficiently to allow excitation of the rhodamine fluorophore by the fluorescein fluorophore. The emission of the rhodamine fluorophore at 560 nm was then monitored as the energy transfer signal. In the presence of 100 nmol/L fluorescein-labeled factor Va, a 5 nmol/L-concentration of rhodamine EGRck factor Xa generated a well-defined energy transfer signal on the membranes of adherent platelets (Fig 6) . The signal was dependent on factor Xa and increased with increasing factor Xa concentrations. In the control sample, with unlabeled factor Va, titration with rhodamine EGRck Xa yielded no signal (Fig 6) . Hence, there was no direct excitation of the rhodamine probe. aBFV-4, an anti-factor Va antibody that inhibits the factor Va/factor Xa interaction in the bovine system, was used to test for specific factor Va/factor Xa interactions. After the energy transfer reaction was established on adherent platelets with 100 nmol/L fluorescein factor Va and 100 nmol/L rhodamine ERGck factor Xa, 4 /umol/L aBFV-4 was added to the well to inhibit the reaction. Virtually complete loss of the signal was seen. Thrombin stimulation of the adherent platelets decreased the energy transfer signal by approximately 7%, probably due to competition for rhodamine EGRck Xa between unlabeled platelet-released factor Va and the added fluorescein-labeled factor Va. Energy transfer between fluorescein-labeled factor Va and rhodaminelabeled factor Xa provided a direct assessment of prothrombinase complex assembly on adherent and thrombin-stimulated adherent platelets. A K A of 4.0±0.4 nmol/L was estimated for the factor Va/factor Xa interaction of the membranes of adherent platelets.
Discussion
In vivo, unactivated platelets remain in suspension as part of the fluid blood flow. However, when perturbed due to vascular injury, platelets adhere and aggregate at the site of damage. We have developed a static, adherent platelet model to mimic the in vivo platelet response under flow conditions in the initial phase of injury repair, ie, the deposition phase during which platelets adhere to a surface but do not spread or release granule contents. 4041 The vWf-adherent platelets approximate conditions under which platelets adhere to exposed subendothelial components in the absence of prior stimulation by agonists such as thrombin. This model system has the advantage of distinguishing between adherent (not fully stimulated) and activated, adherent platelets (fully stimulated), which is not possible with flow systems in which adherence results in platelet activation. 65 ' 66 TIRFS was used to investigate the assembly of the prothrombinase complex, in real time, on the membranes of adherent and thrombin-stimulated adherent human platelets in the model system. To directly observe complex assembly, an energy transfer system was developed with fluorescein-labeled bovine factor Va and rhodamine-labeled bovine factor Xa. Bovine proteins were chosen for the binding study because of the availability of aBFV-4, an anti-bovine factor Va antibody that inhibits the binding of factor Xa to factor Va. 55 - 56 The antibody is specific for bovine factor Va and has no inhibitory effect on prothrombinase activity in clotting assays with human plasma. aBFV-4 allowed definitive assessment of specific factor Va/factor Xa interactions on the platelet surface. The antibody also allowed for discrimination between added bovine factor Va and platelet-released human factor Va. (Human platelets contain factor V in their a-granules, 69 and they release the cofactor on activation.
6970 )
The binding of the protein components of the prothrombinase complex, factors Va and Xa, were first ) are required for maximal prothrombinase activity on platelets. 73 The factor Va binding data obtained by TIRFS also suggested that neither source of factor Va could by itself saturate the available factor Va binding sites. The results of the TIRFS study of the binding of factor Va to adherent platelets were similar to those observed previously for bovine platelets in suspension. 74 However, previous activity studies have been unable to determine a saturation point for the human factor Va/platelet membrane interaction. 3075 Below 21 nmol/L, the approximate plasma concentration of factor V, 72 the TIRFS data also indicated that factor Va binding is nonsaturable. By continuing the titration in excess of the plasma level of the protein, a saturation point was reached, and a K A value could be determined. The K A of 58 nmol/L estimated from the TIRFS study is approximately 50-fold higher than that reported by noncontinuous, nonsaturable binding and activity measurements. 307475 Because traditional assay techniques involve separation of bound and free ligand, weak interactions are not detectable. TIRFS binding studies measure not only higher-affinity binding, such as that reported with traditional binding studies, but also lower-affinity binding, which may not be detected in the traditional, separation-based assays. The TIRFS signal represents the total signal from all types of surface associations. The K a value estimated for factor Va interaction with adherent and thrombin-stimulated adherent platelets therefore represents an average K d for higher affinity and lower affinity interactions. Fluorescence polarization measurements of the binding of labeled factor Va to synthetic phospholipid vesicles show a K d of 2.7 nmol/L for the interaction. 42 Again, the K a determined by TIRFS measurements was approximately 20-fold higher. The greater number of lower affinity sites may weight the determined K d value.
The binding of factor Xa to unstimulated adherent platelets was dependent on the presence of added factor Va. Little factor Xa binding was detected in the absence of added factor Va, indicating that release of platelet factor Va did not occur as a result of the adherence event. After thrombin stimulation of the adherent plate-lets, factor Xa binding was detected without the addition of factor Va. It is interesting to note that factor Xa binding was not saturable on thrombin-stimulated adherent platelets, even in the presence of a thrombin inhibitor.
The factor Xa binding results are similar to those reported in previous studies of platelets in suspension in the sense that little factor Xa binding is observed on unstimulated platelets in suspension 76 ; however, on stimulated platelets in suspension, the release of platelet factor Va supplies a necessary component of the factor Xa binding site, 3176 and a high-affinity, saturable factor Xa interaction is measured. On synthetic phospholipid vesicles, the binding of factor Xa has been reported to have a K a of 470 nmol/L. 77 Factor Xa binding on the thrombin-stimulated adherent platelet membrane, which supplies factor Va to complete the factor Xa binding site, differs substantially from the binding of factor Xa to activated platelets in suspension or in a purely synthetic system. The factor Xa binding detected by TIRFS probably does not represent functional complex assembly between factor Xa and platelet-released factor Va, but it may represent low-affinity factor Xa/platelet membrane interactions that serve to promote functional complex assembly with plateletbound factor Va.
Prothrombinase complex assembly on the membranes of adherent platelets was directly observed through an energy transfer phenomenon between fluorescein-labeled factor Va and rhodamine-labeled factor Xa. Because factors Va and Xa form a distinct complex on the membrane surface, they are held in a set orientation at close proximity, which allows for energy transfer between their respective fluorescent probes. The fluorescein probe on factor Va was directly excited by the incident light beam (wavelength, 488 nm). The fluorescein emission at 520 nm was capable of exciting the rhodamine probe on factor Xa. The rhodamine emission was then detected as the energy transfer signal. Although factor Va and factor Xa binding have been measured separately and simultaneously on platelets in suspension, 293 '-74 -76 direct evidence for complex assembly on adherent platelets has not previously been shown. The energy transfer signal detected was due to the specific interaction of factors Va and Xa on the platelet surface. No signal from rhodamine EGRck Xa was detected in the presence of unlabeled factor Va, indicating there was no direct excitation of the rhodamine probe on factor Xa. aBFV-4, an anti-bovine factor Va antibody that blocks the factor Va/factor Xa interaction, significantly decreased the energy transfer signal. Consequently, the signal did not arise simply due to close proximity, without complex formation, of the molecules on the platelet membrane. By using nonstimulated adherent platelets for this study, the binding of labeled factor Xa to unlabeled platelet-released factor V/Va was minimized. A K6 value of 4 nmol/L was estimated for the factor Va/factor Xa interaction on adherent platelets. This interaction has been reported to have a K d of approximately 1 nmol/L on platelets in suspension. 29 ' 30 The K d values between the traditional and the TIRFS studies were very close in this case because the factor Va/factor Xa interaction on the platelet surface involves a single high-affinity interaction, unlike the binding of factor Va, which involves high-and lowaffinity interactions. The binding of factor Xa to the platelet surface in the absence of added factor Va may also represent several types of interactions.
Thrombin stimulation of the adherent platelets resulted in a small decrease in the energy transfer signal. The decrease in the signal could be due to competition between added labeled factor Va and unlabeled platelet-released factor Va for the rhodamine EGRck factor Xa or to the release of microvesicles containing prothrombinase complexes from the platelet surface. There has been some question about whether platelets or platelet-released microvesicles support the major portion of prothrombinase activity in vivo. Microvesicles are released from platelets in suspension as a consequence of platelet activation. 7881 These particles may contain as much as 50% of the total prothrombinase activity (platelet activity and microvesicle activity), depending on the agonist used to stimulate the platelets. 82 Microvesicles released from the adherent platelets on thrombin stimulation could result in a decrease in the energy transfer signal used to measure the prothrombinase complex assembly on the platelet surface. Additional experiments 83 show that microvesicle release is probably not responsible for the decrease in the energy transfer signal seen subsequent to platelet stimulation with thrombin. The approximately 7% decrease in the signal is most likely due to competition for factor Xa.
Although adherent platelets and thrombin-stimulated adherent platelets support equivalent binding of the prothrombinase complex, it is not known if the activity of the complex is dependent on platelet activation. This link has been reported for human platelets in suspension. 29 The adherence of platelets at sites of vascular injury in vivo, however, may provide for prothrombinase complex assembly before generation of thrombin. The thrombin generated by the complexes on adherent platelets could then serve to induce additional platelets in the vascular flow to aggregate and further promote the repair process. The technique of TIRFS will be able to provide additional information, in real time, on the reactions that occur on the membrane surfaces of adherent platelets and other cells involved in the coagulation response under conditions that mimic aspects of those reactions in vivo.
